ZA200704035B - Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy - Google Patents

Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy

Info

Publication number
ZA200704035B
ZA200704035B ZA200704035A ZA200704035A ZA200704035B ZA 200704035 B ZA200704035 B ZA 200704035B ZA 200704035 A ZA200704035 A ZA 200704035A ZA 200704035 A ZA200704035 A ZA 200704035A ZA 200704035 B ZA200704035 B ZA 200704035B
Authority
ZA
South Africa
Prior art keywords
radionuclide
combination therapy
cytotoxic agent
liposomes enclosing
liposomes
Prior art date
Application number
ZA200704035A
Other languages
English (en)
Inventor
Larsen Roy
Jonasdottir Thora Johanna
Original Assignee
Algeta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta As filed Critical Algeta As
Publication of ZA200704035B publication Critical patent/ZA200704035B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200704035A 2004-10-22 2005-10-21 Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy ZA200704035B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0423565.1A GB0423565D0 (en) 2004-10-22 2004-10-22 Formulation

Publications (1)

Publication Number Publication Date
ZA200704035B true ZA200704035B (en) 2008-08-27

Family

ID=33485085

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200704035A ZA200704035B (en) 2004-10-22 2005-10-21 Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy

Country Status (17)

Country Link
US (1) US20080193374A1 (xx)
EP (1) EP1812115B1 (xx)
JP (1) JP5615483B2 (xx)
KR (2) KR20070108851A (xx)
CN (1) CN101060886A (xx)
AU (1) AU2005297082B2 (xx)
BR (1) BRPI0517006A (xx)
CA (1) CA2583367C (xx)
EA (1) EA011715B1 (xx)
ES (1) ES2424844T3 (xx)
GB (1) GB0423565D0 (xx)
IL (1) IL182634A (xx)
MX (1) MX2007004542A (xx)
NO (1) NO20072529L (xx)
NZ (1) NZ582713A (xx)
WO (1) WO2006043083A2 (xx)
ZA (1) ZA200704035B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644049B1 (en) 2003-04-30 2007-09-26 Ramot at Tel Aviv University Ltd. Method and device for radiotherapy
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
IN2012DN01449A (xx) * 2009-07-17 2015-06-05 Univ Denmark Tech Dtu
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
WO2012079582A1 (en) 2010-12-14 2012-06-21 Technical University Of Denmark Entrapment of radionuclides in nanoparticle compositions
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
WO2014039874A2 (en) * 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
CA2895356A1 (en) * 2012-12-19 2014-06-26 Bayer Pharma Aktiengesellschaft Combination comprising radium-223 for the treatment of cancer
US9795621B2 (en) 2012-12-20 2017-10-24 Carnegie Mellon University Methods and materials for reducing organ transplant rejection or ischemic/reperfusion injury in a subject
EP3258917B1 (en) 2015-02-19 2022-12-21 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
US9433690B1 (en) * 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
WO2016135200A1 (en) * 2015-02-26 2016-09-01 Sciencons AS Radiopharmaceutical solutions with advantageous properties
HUE034806T2 (en) 2015-07-03 2018-02-28 Oncoinvent As Radiotherapy Particles and Suspensions
KR102560243B1 (ko) 2017-05-11 2023-07-27 알파 타우 메디컬 리미티드 근접치료 디바이스용 폴리머 코팅
AU2019247818B2 (en) 2018-04-02 2021-10-14 Alpha Tau Medical Ltd. Controlled release of radionuclides
EP4213826A1 (en) * 2020-09-15 2023-07-26 Oncoinvent AS Preparations of radium-224 and progenies for use in radionuclide therapy in combination with dna repair inhibitors
WO2022130195A1 (en) 2020-12-16 2022-06-23 Alpha Tau Medical Ltd. Diffusing alpha-emitters radiation therapy with enhanced beta treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
DE60135743D1 (de) * 2000-06-16 2008-10-23 Sloan Kettering Inst Cancer Liposomale einkapselung von alphastrahlern, und deren verwendung
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
CA2490959C (en) * 2002-07-02 2013-04-16 Board Of Regents, The University Of Texas System Radiolabeled compounds and liposomes and their methods of making and using the same
US7254229B2 (en) * 2003-03-07 2007-08-07 Legerity, Inc. Method and apparatus for an active impedance feedback
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy

Also Published As

Publication number Publication date
KR20130019029A (ko) 2013-02-25
EP1812115A2 (en) 2007-08-01
EA200700686A1 (ru) 2007-10-26
JP2008517049A (ja) 2008-05-22
GB0423565D0 (en) 2004-11-24
NO20072529L (no) 2007-05-18
CN101060886A (zh) 2007-10-24
WO2006043083A2 (en) 2006-04-27
JP5615483B2 (ja) 2014-10-29
US20080193374A1 (en) 2008-08-14
CA2583367A1 (en) 2006-04-27
AU2005297082A1 (en) 2006-04-27
CA2583367C (en) 2014-09-16
EP1812115B1 (en) 2013-05-15
IL182634A0 (en) 2007-07-24
BRPI0517006A (pt) 2008-09-30
KR20070108851A (ko) 2007-11-13
EA011715B1 (ru) 2009-04-28
IL182634A (en) 2016-03-31
MX2007004542A (es) 2007-08-17
WO2006043083A8 (en) 2007-09-27
WO2006043083A3 (en) 2007-01-04
ES2424844T3 (es) 2013-10-09
AU2005297082B2 (en) 2011-11-17
NZ582713A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
IL182634A0 (en) Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy
TWI350175B (en) Mesothelioma therapeutic agent
GB0416396D0 (en) Therapeutic agents
GB0419850D0 (en) Therapeutic agents
GB0403780D0 (en) Therapeutic agents
GB0310401D0 (en) Therapeutic agent
GB0323378D0 (en) Therapeutic agent
GB0419192D0 (en) Therapeutic agents
GB0423103D0 (en) Therapeutic agents
PL397022A1 (pl) Środek leczniczy
IL165725A0 (en) Immunotoxin as a therapeutic agent and uses thereof
GB0417939D0 (en) Therapeutic agents
GB0400193D0 (en) Therapeutic agents
GB0307333D0 (en) Therapeutic agent
GB0416934D0 (en) Therapeutic agents
GB0400196D0 (en) Therapeutic agents
GB0402918D0 (en) Therapeutic agents
GB0303084D0 (en) Chrystalline therapeutic agent
GB0310402D0 (en) Therapeutic agent
GB0307335D0 (en) Therapeutic agent
EP1627632A4 (en) THERAPEUTIC AGENT
GB0408959D0 (en) Therapeutic agent
GB0207509D0 (en) Therapeutic agent
GB0400198D0 (en) Therapeutic agents
GB0407671D0 (en) Therapeutic agents